Table 1.
Respondent rates in Italy, the EU, and the USA
| Italy | EU | USA | P | |
|---|---|---|---|---|
| Number of respondents | 947 | 147 | 730 | Italy and USA vs. EU <0.001 |
| Ultrasound | 92.1% | 70.6% | 25.8% | Italy vs. EU and vs. USA <0.01 |
| Scan | 25.2% | 31.5% | 41.9% | Italy and EU vs. USA <0.01 |
| RAIU | 11.5% | 6.2% | 47.0% | <0.001 |
| β-Adrenergic blocking agents | 94.8% | 93.6% | 91.9% | n.s. |
| MMI as preferred ATD | 97.7% | 79.3% | 83.5% | n.s. |
| MMI starting dose (20–30 mg) | 57.7% | 67.3% | 68.8% | n.s. |
| PTU as preferred ATD | 1.4% | 2.9% | 2.7% | n.s. |
| Monitor TSH in 4–6 weeks | 67.9% | 30.9% | 68.3% | EU vs. Italy and USA <0.05 |
| Long-term TSH monitor (2–3 months) | 87.5% | 83.1% | 90.1% | n.s. |
| Monitor liver enzymes | 77.7% | 42.3% | 53.8% | Italy vs. EU and vs. USA <0.001 |
| Monitor CBC | 88.4% | 57.8% | 48.4% | Italy vs. EU and vs. USA <0.001 |
| Change ATD for pruritic macular rash | 83.6% | 55.3% | 75.3% | Italy and EU and vs. USA <0.001 |
| Duration treatment with ATD (18 months) | 38.4% | 50.8% | 35.4% | Italy and USA vs. EU <0.001 |
| Stop ATD before RAI (7 days) | 39.5% | 41.2% | 37.1% | n.s. |
| ATD not used after RAI | 29.9% | 19.1% | 31.9% | Italy and USA vs. EU <0.05 |
| Render patient euthyroid preoperatively | 98.4% | 94.2% | 91.2% | n.s. |
| Use Lugol's solution preoperatively | 35.6% | 37.0% | 37.0% | n.s. |
| Vitamin D + calcium postoperatively | 53.6% | 30.7% | 39.3% | Italy vs. EU and vs. USA <0.001 |
| Ophthalmologist consultation | 76.9% | 66.4% | 81.1% | Italy and USA vs. EU <0.001 |
| Orbital imaging | 30.2% | 29.9% | 16.1% | Italy and EU vs. USA <0.01 |
| Steroids administered by endocrinologist | 80.1% | 83.2% | 60.9% | Italy vs. EU and vs. USA <0.001 |
| Use of PTU in first trimester pregnancy | 82.2% | 75.3%% | 75.6% | n.s. |
| Switch PTU-MMI in second trimester | 47.2% | 60.0% | 45.9% | n.s. |